Skip to main content

STRATEGY TO INHIBIT TGF-Beta IN LIVER DISEASE

Objective

Chronic liver diseases (CLD) and their end-stages, cirrhosis and hepatocellular carcinoma (HCC), are leading causes of morbidity and mortality worldwide with enormous socio-economic costs. Patients with liver cirrhosis are at high risk of deadly hepatic failure and over 80% of HCC develop on a cirrhotic background. HCC ranks as the 5th most common cancer and with >600,000 deaths per annum it constitutes a major global health problem. The main etiologies of CLD are chronic HCV and HBV infections, alcohol abuse and nonalcoholic steatohepatitis (NASH) as a result of the metabolic syndrome taking epidemic proportions. Liver transplantation is currently the only available therapy for terminal liver failure.
It is well recognized that the cytokine TGF-Beta plays a pivotal role in the sequence of events leading to end-stage CLD, but the complexity of the underlying aberrant responses in the cells and the organ that lead to the drastic changes seen in CLD and HCC is poorly understood.
A broad spectrum of scientific and technological capacities is needed to accomplish the goal of discovering drugs and treatment modalities for CLD and HCC.As a result, there is a lack – in academia and industry alike - of internationally oriented researchers and research leaders, capable of seamless and bi-directional transfer of goal-oriented scientific knowledge and technologies between the basic, translational and clinical research and industrial capacities; a conditio sine qua non for effectively and efficiently combating CLD and HCC and alleviate its medical and socio-economic burdens. Consequently, the ITN formulated the mission to provide a multidisciplinary and intersectorial Research Training Programme for talented young researchers, so as to prepare them for leading roles in CLD research and drug discovery in European industry and academia.

Call for proposal

FP7-PEOPLE-2012-ITN
See other projects for this call

Coordinator

FUNDACIO INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE
Address
Avenida Gran Via Hospitalet 199-203
08908 L'hospitalet De Llobregat
Spain

See on map

Activity type
Research Organisations
Administrative Contact
Lauren Fleming (Mrs.)
EU contribution
€ 598 655,94

Participants (10)

UNIVERSITA DEGLI STUDI DI BARI ALDO MORO
Italy
EU contribution
€ 510 275,92
Address
Piazza Umberto I 1
70121 Bari

See on map

Activity type
Higher or Secondary Education Establishments
Administrative Contact
Gianelli Gianluigi (Prof.)
ACADEMISCH ZIEKENHUIS LEIDEN
Netherlands
EU contribution
€ 265 461,46
Address
Albinusdreef 2
2333 ZA Leiden

See on map

Activity type
Higher or Secondary Education Establishments
Administrative Contact
Karin Wibier (Ms.)
MEDIZINISCHE UNIVERSITAET WIEN
Austria
EU contribution
€ 262 201,72
Address
Spitalgasse 23
1090 Wien

See on map

Activity type
Higher or Secondary Education Establishments
Administrative Contact
Christoph Zielinski (Prof.)
UPPSALA UNIVERSITET
Sweden
EU contribution
€ 277 525,16
Address
Von Kraemers Alle 4
751 05 Uppsala

See on map

Activity type
Higher or Secondary Education Establishments
Administrative Contact
Marianne Wigenius (Ms.)
RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG
Germany
EU contribution
€ 490 887,76
Address
Seminarstrasse 2
69117 Heidelberg

See on map

Activity type
Higher or Secondary Education Establishments
Administrative Contact
Ralf Weigel (Dr.)
UNIVERSIDAD COMPLUTENSE DE MADRID
Spain
EU contribution
€ 237 681,62
Address
Avenida De Seneca 2
28040 Madrid

See on map

Activity type
Higher or Secondary Education Establishments
Administrative Contact
María Isabel Rodríguez Villa (Mrs.)
CONSIGLIO NAZIONALE DELLE RICERCHE
Italy
EU contribution
€ 251 837,96
Address
Piazzale Aldo Moro 7
00185 Roma

See on map

Activity type
Research Organisations
Administrative Contact
Paola Corezzola (Dr.)
DIGNA BIOTECH, S.L

Participation ended

Spain
Address
Avenida Pio Xii 22 Officina 2
31008 Pamplona
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Gonzalo Barbero (Mr.)
GALAPAGOS BV
Netherlands
EU contribution
€ 215 856,74
Address
Darwinweg 24
2333CR Leiden

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Richard Janssen (Dr.)
GENXPRO GMBH
Germany
EU contribution
€ 201 800,72
Address
Altenhofter Allee 3
60438 Frankfurt

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Peter Winter (Dr.)